Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: A systematic review and meta-analysis

Epilepsia

Volumn 52, Issue 7, 2011, Pages 1280-1291

  Costa, João ^a,b   Fareleira, Filipa ^a   Ascena̧ão, Raquel ^a   Borges, Margarida ^a,b   Sampaio, Cristina ^b   Vaz Carneiro, António ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Anticonvulsants; Comparative effectiveness research; Epilepsies; Meta analysis; Partial

Indexed keywords

ANTICONVULSIVE AGENT; ESLICARBAZEPINE; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO; PREGABALIN; TIAGABINE; TOPIRAMATE; ZONISAMIDE;

CLINICAL EVALUATION; COMPARATIVE STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; FOCAL EPILEPSY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PHARMACOECONOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

AMINES; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; EPILEPSIES, PARTIAL; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; NIPECOTIC ACIDS; PIRACETAM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79960010513     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2011.03047.x     Document Type: Review

References (42)

1. Alexander GC, Stafford RS,. (2009) Does comparative effectiveness have a comparative edge? JAMA 301: 2488-2490.
2. Beghi E,. (2004) Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 3: 618-621. (Pubitemid 39221928)
3. Beyenburg S, Stavem K, Schmidt D,. (2010) Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 51: 7-26.
4. Bialer M, White HS,. (2010) Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 9: 68-82.
5. Bootsma HP, Coolen F, Aldenkamp AP, Arends J, Diepman L, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M,. (2004) Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 5: 380-387. (Pubitemid 38950098)
6. Bootsma HP, Vos AM, Hulsman J, Lambrechts D, Leenen L, Majoie M, Savelkoul M, Schellekens A, Aldenkamp AP,. (2008a) Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 12: 262-268.
7. Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M, Aldenkamp AP,. (2008b) Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison. Seizure 17: 19-26. (Pubitemid 350256997)
8. Brandt C, May TW, Pohlmann-Eden B, Nieder E, Elsner H, Witte-Boelt K, Schuermann I, Ebner A,. (2009) Retention rate of pregabalin in drug-resistant epilepsy: 1-year follow-up, single-centre observation in 105 consecutive, adult patients. Seizure 18: 634-638.
9. Bucher HC, Guyatt GH, Griffith LE, Walter SD,. (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50: 683-691. (Pubitemid 27341818)
10. Carreño M, Maestro I, Molins A, Donaire A, Falip M, Becerra JL, Castillo J,. (2007) Pregabalin as add-on therapy for refractory partial seizures in every day clinical practice. Seizure 16: 709-712. (Pubitemid 350018666)
11. Castillo S, Schmidt DB, White S,. (2000) Oxcarbazepine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev (3): CD002028.
12. Chadwick DW, Marson AG,. (2005) Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev (4): CD001416.
13. Chaisewikul R, Privitera MD, Hutton JL, Marson AG,. (2001) Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane Database Syst Rev (1): CD001901.
14. Cho YJ, Heo K, Kim WJ, Jang SH, Jung YH, Ye BS, Song DB, Lee BI,. (2009) Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia 50: 1910-1919.
15. Chung S, Wang N, Hank N,. (2007) Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 16: 296-304. (Pubitemid 46614649)
16. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ,. (2009) Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 302: 1437-1443.
17. Deeks JJ, Altman DG, Bradburn MJ,. (2001) Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In, Egger M, Davey Smith G, Altman DG, (Eds) Systematic reviews in health care: meta-analysis in context, 2nd ed. BMJ Publication Group, London, pp. 313-335.
18. Depondt C, Yuen AW, Bell GS, Mitchell T, Koepp MJ, Duncan JS, Sander JW,. (2006) The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 77: 101-103. (Pubitemid 43022705)
19. DerSimonian R, Laird N,. (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
20. French JA, Faught E,. (2009) Rational polytherapy. Epilepsia 50: 63-68.
21. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Bradburn M, Eastwood AJ,; International Stroke Trial Collaborative Group. (2005) Indirect comparisons of competing interventions. Health Technol Assess 9: 1e144.
22. Ioannidis JP,. (2006) Indirect comparisons: the mesh and mess of clinical trials. Lancet 368: 1470-1472. (Pubitemid 44634678)
23. Jette N, Hemming K, Hutton JL, Marson AG,. (2008) Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev (3): CD001417.
24. Kwan P, Sperling MR,. (2009) Refractory seizures: try additional antiepileptic drugs (after two have failed) or go directly to early surgery evaluation? Epilepsia 50: 57-62.
25. Lhatoo SD, Wong IC, Polizzi G, Sander JW,. (2000) Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 41: 1592-1596. (Pubitemid 32002733)
26. Lozsadi D, Hemming K, Marson AG,. (2008) Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev (1): CD005612.
27. Marson AG, Kadir ZA, Hutton JL, Chadwick DW,. (2000) Gabapentin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev (3): CD001415.
28. Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, Schneeweiss S,. (2010) Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 303: 1401-1409.
29. Pereira J, Marson AG, Hutton JL,. (2002) Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev (3): CD001908.
30. Perucca E, French J, Bialer M,. (2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6: 793-804. (Pubitemid 47243712)
31. Radhakrishnan K,. (2009) Challenges in the management of epilepsy in resource-poor countries. Nat Rev Neurol 5: 323-330.
32. Ramaratnam S, Marson AG, Baker GA,. (2001) Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev (3): CD001909.
33. Schuele SU, Lüders HO,. (2008) Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 7: 514-524. (Pubitemid 351657492)
34. Seneviratne U, D'Souza W, Cook M,. (2008) Long-term assessment of oxcarbazepine in a naturalistic setting: a retrospective study. Acta Neurol Scand 117: 367-369. (Pubitemid 351503328)
35. Song F, Altman DG, Glenny AM, Deeks JJ,. (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 326: 472-475. (Pubitemid 36269627)
36. Song F, Harveya I, Lilfordc R,. (2008) Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 61: 455-463. (Pubitemid 351446184)
37. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG,. (2009) Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. Br Med J 338: b1147.
38. Valentin A, Moran N, Hadden R, Oakes A, Elwes R, Delamont R, Mullatti N, Nashef L,. (2009) Pregabalin as adjunctive therapy for partial epilepsy: an audit study in 96 patients from the South East of England. Seizure 18: 450-452.
39. Wong ICK,. (1997) New antiepileptic drugs: study suggests that a quarter of patients will still be taken the new drugs after six years. Br Med J 314: 603-604.
40. Wong IC, Chadwick DW, Fenwick PB, Mawer GE, Sander JW,. (1999) The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. Epilepsia 40: 1439-1445. (Pubitemid 29471345)
41. Wroe SJ, Yeates AB, Marshall A,. (2008) Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. Acta Neurol Scand 118: 87-93.
42. Zaccara G, Messori A, Cincotta M, Burchini G,. (2006) Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 114: 157-168. (Pubitemid 44185908)